Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information.

GILEAD | Medical Information

# Trodelvy® (sacituzumab govitecan-hziy) Use of an Alternative Solution for Reconstitution and Dilution

This document is in response to your request for information regarding the use of an alternative solution for the reconstitution and dilution of Trodelvy® (sacituzumab govitecan-hziy [SG]).

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

**The full indication, important safety information, and boxed warnings for neutropenia and diarrhea are available at: www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.**

## Relevant Product Labeling[1]

## Dosage and Administration

### Preparation and administration

#### *Reconstitution*

SG is a hazardous drug. Follow applicable special handling and disposal procedures.

Using a sterile syringe, slowly inject 20 mL of 0.9% sodium chloride injection, USP, into each 180 mg SG vial. Each vial contains overfill to compensate for liquid loss during preparation and after reconstitution, the total resulting volume delivers a concentration of 10 mg/mL

#### *Dilution*

Determine the final volume of the infusion solution to deliver the appropriate dose at a SG concentration range of 1.1 to 3.4 mg/mL

Use 0.9% sodium chloride injection, USP only since the stability of the reconstituted SG solution has not been determined with other infusion-based solutions. Use a polyvinyl chloride, polypropylene/polyethylene, polyolefin, or ethylene vinyl acetate infusion bag.

Withdraw and discard the volume of 0.9% sodium chloride injection, USP from the final infusion bag that is necessary to achieve the indicated SG concentration following the addition of the calculated amount of reconstituted SG solution.

Withdraw the calculated amount of the reconstituted SG solution from the vial(s) using a syringe. Discard any unused portion remaining in the vial(s).

Please refer to the attached US FDA-approved Prescribing Information for additional details pertaining to the reconstitution and dilution of SG.

## Additional Information

No information is available regarding the use of alternative solutions for the reconstitution and/or dilution of SG.

Gilead cannot provide alternative recommendations or suggestions for reconstitution/dilution solutions, outside of those recommended in the US FDA-approved Prescribing Information.

Gilead cannot recommend the use of SG under circumstances where reconstitution and/or dilution is carried out in a manner that is not consistent with the US FDA-approved Prescribing Information.

## References

1. TRODELVY, Gilead Sciences Inc. TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use, U.S. Prescribing Information. Foster City, CA.

## Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Trodelvy US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.

## Follow-Up

For any additional questions, please contact Trodelvy Medical Information at:

☎1-888-983-4668 or 🖱 www.askgileadmedical.com

## Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or 🖱 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🖱 www.accessdata.fda.gov/scripts/medwatch

## Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite

product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries other than your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com

TRODELVY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
© 2024 Gilead Sciences, Inc.